Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

NCT07389629 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Iparomlimab and Tuvonralimab
Clear Cell Renal Cell Carcinoma
Neoadjuvant Therapy

Interventions

DRUG: QL1706 Combined With Lenvatinib

Sponsor

Sun Yat-sen University